Chapter 6 First Episode Psychosis and Cognition

Gilberto Sousa Alves

https://orcid.org/0000-0002-0463-6183 Federal University of Rio de Janeiro, Brazil

Romulo Kunrath Pinto Silva

Nina Rodrigues Hospital, Brazil

Marielia Barbosa Freitas Leal

Federal University of Ceará, Brazil

Bianca de Melo Ferro

Federal University of Maranhao, Brazil

Leandro de Oliveira Trovão

Nina Rodrigues Hospital, Brazil

ABSTRACT

The experience of the psychosis can open a critical window into primary psychiatric conditions, particularly schizophrenia or bipolar disorder. More recently, the role of environment in early adolescence or late childhood, including psychological abuse or physical violence, has been associated with a greater likelihood of developing psychosis years later. Evidence has also shown, even in symptomatic remission, the occurrence of cognitive symptoms, particularly in complex attention, executive functioning, episodic memory, and verbal and procedural IQ. The current chapter discusses the epidemiology of first episode psychosis, neurobiological characteristics, and main risk factors, including early exposure to the trauma situation and early interventions.

DOI: 10.4018/979-8-3693-0851-6.ch006

INTRODUCTION

Psychosis can be conceptualized as a combination of symptoms resulting in a disconnection of reality and a severe impact on an individual's functionality and quality of life. The experience of the psychotic phenomenon can open a critical window into primary psychiatric conditions, particularly schizophrenia, schizoaffective disorder, or bipolar disorder. The use of psychoactive substances, such as marijuana, cocaine, and synthetic drugs (LSD, MDMA), as well as a variety of infectious, autoimmune, and vascular medical conditions, among others, may be related to psychotic episodes as etiological or predisposing factors. More recently, the role of environmental experiences in early adolescence or late childhood, including psychological abuse or physical violence, has been associated with a greater likelihood of developing psychosis years later. The emergence of first-episode psychosis (FEP) varies widely, usually occurring at the end of adolescence and the beginning of adult life. The operational concept of first-episode psychosis usually encompasses a wide range of categories: first treatment contact, duration of antipsychotic medication, and duration of psychotic episode (Breitborde et al., 2009). A determining factor for progression to severe symptoms is the intensity of psychotic symptoms, such as delusions and hallucinations. In addition to behavioral symptoms, psychotic conditions are often accompanied by negative symptoms (reduced emotional expression, sociability, avolition, and anhedonia). Furthermore, evidence has shown, even in individuals with symptomatic remission, the occurrence of cognitive symptoms, particularly in complex attention, executive functioning, episodic memory, and verbal and procedural IQ, among others. The current chapter discusses factors such as the epidemiology of FEP, neurobiological characteristics, and main risk factors, including early exposure to the trauma situation and early interventions.

1. Prevalence of Psychosis in Adolescents and Early Adulthood

Psychosis, from a broader perspective, affects approximately 3% of the global population, with schizophrenia representing its most severe and prevalent form, affecting approximately 1% of individuals throughout their lives (McCleery & Nuechterlein, 2019). Adolescence represents a significant sociocultural phenomenon associated with psychological reshaping regarding how individuals perceive themselves and the world. During this period, certain aspects of personality, such as self-concept and self-esteem, develop, influencing preferences and the quest for acceptance within peer groups (Lepre & De Oliveira, 2022).

The neurobiology of FEP may involve the disruption of crucial brain functions, notably affecting fronto-striatal and temporal circuits. Furthermore, its clinical

18 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage: www.igi-

global.com/chapter/first-episode-psychosis-andcognition/342885

Related Content

Tiny Tech, Big Impact: How AI-Enhanced Approaches Can Reshape Food Habits and Support Waste Reduction

Kanwal Gul, Sunita Panicker, Swapnil Morandeand Veena Tewari (2024). Neuroscientific Insights and Therapeutic Approaches to Eating Disorders (pp. 318-327).

www.irma-international.org/chapter/tiny-tech-big-impact/351702

Soft Computing-Based Early Detection of Parkinson's Disease Using Non-Invasive Method Based on Speech Analysis

Chandrasekar Ravi (2019). Early Detection of Neurological Disorders Using Machine Learning Systems (pp. 96-107).

www.irma-international.org/chapter/soft-computing-based-early-detection-of-parkinsons-disease-using-non-invasive-method-based-on-speech-analysis/230112

Linguistic Markers in Individuals With Symptoms of Depression in Bi-Multilingual Context

Anbu Savekar, Shashikanta Taraiand Moksha Singh (2019). *Early Detection of Neurological Disorders Using Machine Learning Systems (pp. 216-240).*www.irma-international.org/chapter/linguistic-markers-in-individuals-with-symptoms-of-depression-in-bi-multilingual-context/230118

Al-Driven Personalized Nutritional and Scams Planning: Food Regulations Laws

Karkuzhali S.and Senthilkumar S. (2024). *Neuroscientific Insights and Therapeutic Approaches to Eating Disorders (pp. 13-31).*

 $\frac{www.irma-international.org/chapter/ai-driven-personalized-nutritional-and-scams-planning/351681$

Neuropathology of Parkinson's Disease: An Update of the Recent Findings

Bilal El-Mansoury, Omar El Hiba, Mustapha Agnaou, Arumugam Radhakrishan Jayakumar, Abdelaati El Khiat, Kholoud Kahim, Samira Boulbaroud, Nadia Zouhairi, Oumaima Tibssirte, Hayat Bouighajd, Moulay Abdelmonaim El Hidan, Abdesslam Ferssiwiand Abdelali Bitar (2023). *Experimental and Clinical Evidence of the Neuropathology of Parkinson's Disease (pp. 82-101).*

www.irma-international.org/chapter/neuropathology-of-parkinsons-disease/327967